Supernus Pharmaceuticals, Inc. (0LB2.L)
USD 30.74
(-2.97%)
USD 30.74
(-2.97%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 607.52 Million USD | -8.95% |
| 2022 | 667.23 Million USD | 15.09% |
| 2021 | 579.77 Million USD | 11.41% |
| 2020 | 520.39 Million USD | 32.5% |
| 2019 | 392.75 Million USD | -3.95% |
| 2018 | 408.89 Million USD | 35.29% |
| 2017 | 302.23 Million USD | 40.57% |
| 2016 | 215 Million USD | 48.87% |
| 2015 | 144.42 Million USD | 18.34% |
| 2014 | 122.04 Million USD | 915.43% |
| 2013 | 12.01 Million USD | 712.09% |
| 2012 | 1.48 Million USD | 84.31% |
| 2011 | 803 Thousand USD | 657.55% |
| 2010 | 106 Thousand USD | -99.72% |
| 2009 | 37.92 Million USD | 326.65% |
| 2008 | 8.88 Million USD | 109.97% |
| 2007 | 4.23 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 175.68 Million USD | 4.37% |
| 2024 Q2 | 168.32 Million USD | 17.18% |
| 2024 Q1 | 143.64 Million USD | -12.58% |
| 2023 Q4 | 164.31 Million USD | 6.78% |
| 2023 Q3 | 153.88 Million USD | 13.51% |
| 2023 Q1 | 153.76 Million USD | -8.11% |
| 2023 Q2 | 135.56 Million USD | -11.84% |
| 2023 FY | 607.52 Million USD | -8.95% |
| 2022 FY | 667.23 Million USD | 15.09% |
| 2022 Q4 | 167.32 Million USD | -5.65% |
| 2022 Q2 | 170.05 Million USD | 11.5% |
| 2022 Q1 | 152.5 Million USD | -4.11% |
| 2022 Q3 | 177.35 Million USD | 4.29% |
| 2021 Q3 | 148.46 Million USD | 5.05% |
| 2021 Q1 | 130.93 Million USD | -8.79% |
| 2021 FY | 579.77 Million USD | 11.41% |
| 2021 Q2 | 141.32 Million USD | 7.94% |
| 2021 Q4 | 159.05 Million USD | 7.13% |
| 2020 Q3 | 155.13 Million USD | 22.41% |
| 2020 Q2 | 126.72 Million USD | 33.43% |
| 2020 Q1 | 94.97 Million USD | -5.45% |
| 2020 FY | 520.39 Million USD | 32.5% |
| 2020 Q4 | 143.55 Million USD | -7.46% |
| 2019 Q1 | 85.47 Million USD | -26.27% |
| 2019 Q3 | 102.14 Million USD | -2.44% |
| 2019 Q2 | 104.69 Million USD | 22.49% |
| 2019 Q4 | 100.44 Million USD | -1.66% |
| 2019 FY | 392.75 Million USD | -3.95% |
| 2018 FY | 408.89 Million USD | 35.29% |
| 2018 Q1 | 90.42 Million USD | 2.25% |
| 2018 Q2 | 99.53 Million USD | 10.07% |
| 2018 Q3 | 102.99 Million USD | 3.47% |
| 2018 Q4 | 115.93 Million USD | 12.56% |
| 2017 Q1 | 57.57 Million USD | -7.69% |
| 2017 Q3 | 80.39 Million USD | 6.03% |
| 2017 Q4 | 88.43 Million USD | 10.0% |
| 2017 FY | 302.23 Million USD | 40.57% |
| 2017 Q2 | 75.82 Million USD | 31.7% |
| 2016 Q3 | 56.81 Million USD | 12.67% |
| 2016 Q2 | 50.42 Million USD | 17.05% |
| 2016 Q1 | 43.07 Million USD | 0.98% |
| 2016 FY | 215 Million USD | 48.87% |
| 2016 Q4 | 62.37 Million USD | 9.79% |
| 2015 Q2 | 35.05 Million USD | 24.59% |
| 2015 Q3 | 38.58 Million USD | 10.08% |
| 2015 Q4 | 42.65 Million USD | 10.55% |
| 2015 FY | 144.42 Million USD | 18.34% |
| 2015 Q1 | 28.13 Million USD | -8.66% |
| 2014 Q4 | 30.8 Million USD | -41.32% |
| 2014 Q3 | 52.48 Million USD | 76.88% |
| 2014 Q2 | 29.67 Million USD | 226.78% |
| 2014 FY | 122.04 Million USD | 915.43% |
| 2014 Q1 | 9.08 Million USD | -12.13% |
| 2013 Q1 | 147 Thousand USD | -86.51% |
| 2013 Q3 | 1.25 Million USD | 347.33% |
| 2013 Q4 | 10.33 Million USD | 722.12% |
| 2013 FY | 12.01 Million USD | 712.09% |
| 2013 Q2 | 281 Thousand USD | 91.16% |
| 2012 Q2 | 91 Thousand USD | -56.25% |
| 2012 Q4 | 1.09 Million USD | 1097.8% |
| 2012 FY | 1.48 Million USD | 84.31% |
| 2012 Q3 | 91 Thousand USD | 0.0% |
| 2012 Q1 | 208 Thousand USD | 102.11% |
| 2011 Q3 | 11 Thousand USD | -98.53% |
| 2011 Q4 | -9.84 Million USD | -89600.0% |
| 2011 FY | 803 Thousand USD | 657.55% |
| 2011 Q2 | 750 Thousand USD | 0.0% |
| 2011 Q1 | - USD | 100.0% |
| 2010 FY | 106 Thousand USD | -99.72% |
| 2010 Q4 | -8.62 Million USD | 0.0% |
| 2009 FY | 37.92 Million USD | 326.65% |
| 2009 Q4 | -5.13 Million USD | 0.0% |
| 2008 FY | 8.88 Million USD | 109.97% |
| 2007 FY | 4.23 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| uniQure N.V. | 15.84 Million USD | -3734.634% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -17257.743% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -1844.129% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 91.109% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -2164.926% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 66.771% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | -52.125% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -6986.446% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -124.509% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 74.888% |
| bluebird bio, Inc. | 29.49 Million USD | -1959.603% |
| Blueprint Medicines Corporation | 249.38 Million USD | -143.613% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -2797.372% |
| Imunon, Inc. | - USD | -Infinity% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | -25.944% |
| Dynavax Technologies Corporation | 232.28 Million USD | -161.542% |
| Editas Medicine, Inc. | 78.12 Million USD | -677.647% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 42.102% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -422.221% |
| Exelixis, Inc. | 1.83 Billion USD | 66.806% |
| FibroGen, Inc. | 147.75 Million USD | -311.176% |
| Geron Corporation | 237 Thousand USD | -256237.975% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | 26.739% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -378.197% |
| Illumina, Inc. | 4.5 Billion USD | 86.512% |
| Incyte Corporation | 3.69 Billion USD | 83.561% |
| Insmed Incorporated | 305.2 Million USD | -99.051% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -1574.765% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | 22.869% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -50995.122% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 95.946% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 83.963% |
| Evolus, Inc. | 202.08 Million USD | -200.626% |
| Myriad Genetics, Inc. | 678.4 Million USD | 10.448% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 67.807% |
| OPKO Health, Inc. | 863.49 Million USD | 29.644% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 51.138% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 99.589% |
| Waters Corporation | 2.95 Billion USD | 79.451% |
| Zoetis Inc. | 8.54 Billion USD | 92.89% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 93.844% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 98.582% |
| Biogen Inc. | 9.83 Billion USD | 93.823% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -244.728% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 95.369% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Homology Medicines, Inc. | -6.65 Million USD | 9234.281% |
| Nektar Therapeutics | 90.12 Million USD | -574.11% |
| TG Therapeutics, Inc. | 233.66 Million USD | -160.0% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Perrigo Company plc | 4.65 Billion USD | 86.951% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |